Table 2.
Medication of the studied patients with RA and ODCTD.
| Characteristics | RA (n = 280) | SLE + MCTD (n = 272) |
|---|---|---|
| Medication, n (%) | ||
| NSAIDs | 117 (41.8%) | 9 (3.3%) |
| csDMARDs, n (%) | ||
| GC | 61 (21.8%) | 165 (60.7%) |
| HCQ | 123 (43.9%) | 201 (73.9%) |
| MTX | 145 (51.8%) | 12 (4.4%) |
| SSZ | 2 (0.7%) | 0 (0%) |
| CTX | 2 (0.7%) | 7 (2.6%) |
| LEF | 52 (18.6%) | 15 (5.5%) |
| AZA | 0 (0%) | 8 (2.9%) |
| MMF | 1 (0.4%) | 58 (21.3%) |
| CsA | 3 (1.1%) | 13 (4.8%) |
| FK506 | 1 (0.4%) | 35 (12.9%) |
| bDMARDs, n (%) | ||
| TNFi | 24 (8.6%) | 0 (0%) |
| RTX | 0 (0%) | 2 (0.7%) |
| IL-6i | 14 (5.0%) | 0 (0%) |
| BlySi | 0 (0%) | 21 (7.7%) |
| IL-17i | 0 (0%) | 0 (0%) |
| tsDMARDs, n (%) | ||
| JAKi | 69 (24.6%) | 8 (%) |
NSAIDs, nonsteroidal antiinflammatory drugs; GC, glucocorticoid; DMARDs, disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HCQ, hydroxychloroquine; MTX, methotrexate; SSZ, sulfasalazine; CTX, cyclophosphamide; LEF, leflunomide; AZA, azathioprine; MMF, mycophenolate mofetil; CsA, cyclosporine; FK506, tacrolimus; bDMARDs, biologic disease-modifying antirheumatic drugs; TNFi, tumour necrosis factor inhibitors; RTX, rituximab; IL-6i, IL-6 inhibitors; BlySi, belimumab; IL-17i, IL-17 inhibitors; tsDMARDs, targeted synthetic disease-modifying antirheumatic drugs; JAKi, Janus Kinase inhibitors.